



Announcement Veklury® (remdesivir)

Gilead Sciences Farmacêutica do Brasil Ltda, holder of the registration for **VEKLURY® (remdesivir)**, informs that it has been experiencing a disruption in the supply chain of this drug since the beginning of February/2025, which is related to unexpected scenarios such as: increased demand for the drug, difficulty in identifying the disease's behavior pattern, in addition to the emergence of new viral variants and subvariants. These factors, combined with a global supply chain, cause a temporary interruption in the supply of components used in the manufacture of the product, specifically in the materials used in the packaging phase. Therefore, the current forecast for normalization of supply is April/2025.

The company understands the importance of **VEKLURY® (remdesivir)** for patients and healthcare professionals and is working to regularize the supply as quickly as possible.

During this period, it is important for patients and doctors to discuss the best approach for the treatment and prevention of COVID-19. ANVISA was notified of this situation on February 11, 2025, as determined by RDC No. 18 of April 4, 2014.